COVIVIO (COV.PA) Stock Fundamental Analysis

EPA:COV • FR0000064578

57.7 EUR
-2.5 (-4.15%)
Last: Mar 3, 2026, 07:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to COV. COV was compared to 43 industry peers in the Diversified REITs industry. COV has a medium profitability rating, but doesn't score so well on its financial health evaluation. COV has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year COV was profitable.
  • In the past year COV had a positive cash flow from operations.
  • Of the past 5 years COV 4 years were profitable.
  • COV had a positive operating cash flow in 4 of the past 5 years.
COV.PA Yearly Net Income VS EBIT VS OCF VS FCFCOV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B -1B

1.2 Ratios

  • COV's Return On Assets of 1.63% is in line compared to the rest of the industry. COV outperforms 46.51% of its industry peers.
  • COV's Return On Equity of 5.08% is in line compared to the rest of the industry. COV outperforms 58.14% of its industry peers.
  • COV's Return On Invested Capital of 3.21% is in line compared to the rest of the industry. COV outperforms 48.84% of its industry peers.
Industry RankSector Rank
ROA 1.63%
ROE 5.08%
ROIC 3.21%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
COV.PA Yearly ROA, ROE, ROICCOV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10

1.3 Margins

  • COV has a Profit Margin (30.46%) which is comparable to the rest of the industry.
  • In the last couple of years the Profit Margin of COV has grown nicely.
  • With a Operating Margin value of 57.81%, COV is not doing good in the industry: 60.47% of the companies in the same industry are doing better.
  • COV's Operating Margin has improved in the last couple of years.
  • With a Gross Margin value of 74.42%, COV perfoms like the industry average, outperforming 58.14% of the companies in the same industry.
  • In the last couple of years the Gross Margin of COV has remained more or less at the same level.
Industry RankSector Rank
OM 57.81%
PM (TTM) 30.46%
GM 74.42%
OM growth 3Y11.41%
OM growth 5Y7.53%
PM growth 3Y16.3%
PM growth 5Y17.87%
GM growth 3Y2.18%
GM growth 5Y0.71%
COV.PA Yearly Profit, Operating, Gross MarginsCOV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

1

2. Health

2.1 Basic Checks

  • COV has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • COV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
COV.PA Yearly Shares OutstandingCOV.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
COV.PA Yearly Total Debt VS Total AssetsCOV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

  • COV has an Altman-Z score of 0.55. This is a bad value and indicates that COV is not financially healthy and even has some risk of bankruptcy.
  • COV's Altman-Z score of 0.55 is on the low side compared to the rest of the industry. COV is outperformed by 67.44% of its industry peers.
  • The Debt to FCF ratio of COV is 28.49, which is on the high side as it means it would take COV, 28.49 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 28.49, COV is doing worse than 65.12% of the companies in the same industry.
  • A Debt/Equity ratio of 1.07 is on the high side and indicates that COV has dependencies on debt financing.
  • COV has a Debt to Equity ratio of 1.07. This is in the lower half of the industry: COV underperforms 74.42% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF 28.49
Altman-Z 0.55
ROIC/WACC0.55
WACC5.85%
COV.PA Yearly LT Debt VS Equity VS FCFCOV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B 10B

2.3 Liquidity

  • A Current Ratio of 0.76 indicates that COV may have some problems paying its short term obligations.
  • COV's Current ratio of 0.76 is fine compared to the rest of the industry. COV outperforms 65.12% of its industry peers.
  • COV has a Quick Ratio of 0.76. This is a bad value and indicates that COV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • COV has a Quick ratio of 0.69. This is in the better half of the industry: COV outperforms 65.12% of its industry peers.
Industry RankSector Rank
Current Ratio 0.76
Quick Ratio 0.69
COV.PA Yearly Current Assets VS Current LiabilitesCOV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

3

3. Growth

3.1 Past

  • COV shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.26%.
  • Measured over the past 5 years, COV shows a small growth in Earnings Per Share. The EPS has been growing by 2.44% on average per year.
  • Looking at the last year, COV shows a very negative growth in Revenue. The Revenue has decreased by -11.71% in the last year.
  • Measured over the past years, COV shows a decrease in Revenue. The Revenue has been decreasing by -2.03% on average per year.
EPS 1Y (TTM)6.26%
EPS 3Y1.22%
EPS 5Y2.44%
EPS Q2Q%6.28%
Revenue 1Y (TTM)-11.71%
Revenue growth 3Y-8.88%
Revenue growth 5Y-2.03%
Sales Q2Q%40.47%

3.2 Future

  • Based on estimates for the next years, COV will show a small growth in Earnings Per Share. The EPS will grow by 2.19% on average per year.
  • COV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.15% yearly.
EPS Next Y0.64%
EPS Next 2Y2.19%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.51%
Revenue Next 2Y5.15%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
COV.PA Yearly Revenue VS EstimatesCOV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
COV.PA Yearly EPS VS EstimatesCOV.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3 4 5

4

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 12.15 indicates a correct valuation of COV.
  • Based on the Price/Earnings ratio, COV is valued a bit cheaper than the industry average as 69.77% of the companies are valued more expensively.
  • COV's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.83.
  • Based on the Price/Forward Earnings ratio of 12.07, the valuation of COV can be described as correct.
  • The rest of the industry has a similar Price/Forward Earnings ratio as COV.
  • COV's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.95.
Industry RankSector Rank
PE 12.15
Fwd PE 12.07
COV.PA Price Earnings VS Forward Price EarningsCOV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • COV's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. COV is cheaper than 65.12% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of COV indicates a slightly more expensive valuation: COV is more expensive than 60.47% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 16.4
EV/EBITDA 17.53
COV.PA Per share dataCOV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates COV does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)19.02
PEG (5Y)4.97
EPS Next 2Y2.19%
EPS Next 3YN/A

4

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 6.11%, COV is a good candidate for dividend investing.
  • COV's Dividend Yield is a higher than the industry average which is at 5.12.
  • COV's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 6.11%

5.2 History

  • The dividend of COV decreases each year by -1.54%.
Dividend Growth(5Y)-1.54%
Div Incr Years2
Div Non Decr Years2
COV.PA Yearly Dividends per shareCOV.PA Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3 4

5.3 Sustainability

  • 92.76% of the earnings are spent on dividend by COV. This is not a sustainable payout ratio.
DP92.76%
EPS Next 2Y2.19%
EPS Next 3YN/A
COV.PA Yearly Income VS Free CF VS DividendCOV.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M -1B
COV.PA Dividend Payout.COV.PA Dividend Payout, showing the Payout Ratio.COV.PA Dividend Payout.PayoutRetained Earnings

COVIVIO

EPA:COV (3/3/2026, 7:00:00 PM)

57.7

-2.5 (-4.15%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryDiversified REITs
Earnings (Last)02-18
Earnings (Next)07-20
Inst Owners42.11%
Inst Owner ChangeN/A
Ins Owners0.27%
Ins Owner ChangeN/A
Market Cap6.44B
Revenue(TTM)1.15B
Net Income(TTM)417.86M
Analysts75
Price Target64.28 (11.4%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 6.11%
Yearly Dividend0.72
Dividend Growth(5Y)-1.54%
DP92.76%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.66%
PT rev (3m)-0.22%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0.32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.2%
Revenue NY rev (3m)2.79%
Valuation
Industry RankSector Rank
PE 12.15
Fwd PE 12.07
P/S 4.7
P/FCF 16.4
P/OCF 6.42
P/B 0.78
P/tB 0.82
EV/EBITDA 17.53
EPS(TTM)4.75
EY8.23%
EPS(NY)4.78
Fwd EY8.28%
FCF(TTM)3.52
FCFY6.1%
OCF(TTM)8.99
OCFY15.58%
SpS12.29
BVpS73.66
TBVpS70.57
PEG (NY)19.02
PEG (5Y)4.97
Graham Number88.73
Profitability
Industry RankSector Rank
ROA 1.63%
ROE 5.08%
ROCE 3.59%
ROIC 3.21%
ROICexc 3.42%
ROICexgc 3.48%
OM 57.81%
PM (TTM) 30.46%
GM 74.42%
FCFM 28.62%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y11.41%
OM growth 5Y7.53%
PM growth 3Y16.3%
PM growth 5Y17.87%
GM growth 3Y2.18%
GM growth 5Y0.71%
F-Score7
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF 28.49
Debt/EBITDA 9.39
Cap/Depr 415.79%
Cap/Sales 44.53%
Interest Coverage 250
Cash Conversion 106.76%
Profit Quality 93.95%
Current Ratio 0.76
Quick Ratio 0.69
Altman-Z 0.55
F-Score7
WACC5.85%
ROIC/WACC0.55
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.26%
EPS 3Y1.22%
EPS 5Y2.44%
EPS Q2Q%6.28%
EPS Next Y0.64%
EPS Next 2Y2.19%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-11.71%
Revenue growth 3Y-8.88%
Revenue growth 5Y-2.03%
Sales Q2Q%40.47%
Revenue Next Year4.51%
Revenue Next 2Y5.15%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.73%
EBIT growth 3Y1.52%
EBIT growth 5Y5.34%
EBIT Next Year7.68%
EBIT Next 3Y7.22%
EBIT Next 5YN/A
FCF growth 1Y-30.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.27%
OCF growth 3YN/A
OCF growth 5YN/A

COVIVIO / COV.PA FAQ

Can you provide the ChartMill fundamental rating for COVIVIO?

ChartMill assigns a fundamental rating of 3 / 10 to COV.PA.


What is the valuation status for COV stock?

ChartMill assigns a valuation rating of 4 / 10 to COVIVIO (COV.PA). This can be considered as Fairly Valued.


Can you provide the profitability details for COVIVIO?

COVIVIO (COV.PA) has a profitability rating of 4 / 10.


What is the financial health of COVIVIO (COV.PA) stock?

The financial health rating of COVIVIO (COV.PA) is 1 / 10.


How sustainable is the dividend of COVIVIO (COV.PA) stock?

The dividend rating of COVIVIO (COV.PA) is 4 / 10 and the dividend payout ratio is 92.76%.